Futura Medical
Management update details degree of 2021 progressAvacta
AVA6000 set to start US Phase I studies in early-2022MaxCyte
Nkarta signs SPL to accelerate its NK cell therapiesAllergy Therapeutics
Positive top line G309 results for Grass MATA MPLRedx Pharma
R&D update: RXC004 and RXC007 in the spotlightANGLE
Poised to disrupt existing tumour assay protocolsAvacta
Foundations for two healthy businesses now in placeFutura Medical
A year of delivery, with key milestones achievedAllergy Therapeutics
FY21 results show continued strong growthArecor Therapeutics
H121 results underline quality of management execution